National and Kapodistrian University of Athens
Μελέτη της φυσικής και προσαρμοσμένης ανοσίας στην παθοφυσιολογία του άσθματος
Abstract
dc:descriptionThe lung interacts constantly with the external environment, thus it is often exposed to dangerous irritants. An irritant may cause tissue damage that stimulates inflammatory mechanisms in order to eliminate the irritant and preserve homeostasis. Sometimes, inflammation is sustained and the system is trapped to a vicious cycle of injury-repair leading to tissue remodeling. Extremely important for the preservation of homeostasis are the mechanisms that regulate the balance of pre/anti-inflammatory and repair mechanisms that are not fully understood. The present study focuses on two molecules the particle in several processes aiming to treat pulmonary diseases that involve inflammatory and repair processes. The first molecule is TLR7, a member of Toll-like receptors (TLRs). It was chosen based on the immunomodulation theory, where microbial exposure can reeducate the immune system towards reduced immune response type 2 to allergens. Moreover, polymorphisms for TLR7 were associated to asthma and related atopic disorders in humans. We administered intranasally in mice a ligand of TLR7, R-848 in the context of well-established models of allergic airway disease. We observed that R-848 was able to suppress the immune response type 2 and the epiphenomena of allergic airway disease in a prophylactic and a therapeutic manner. This suppressive effect remained for up to 1 month after the administration. The analysis of its mode of action revealed that the activation of TLR stimulates rapidly the intense production of interferons type I. Interferons type 1 suppressed immediately the immune response type 2 and the epiphenomena of allergic airway disease. Later on however an immunoregulatory population of CD8+ T cells is induced and confers long-term protection suppressing the immune response type 2 in an IFNγ dependent mechanism. The second molecule is Activin A, which is a member of TGFb superfamily and seems to be involved in inflammatory and repair mechanisms. As high levels of Activin A are detected in several immune and fibrotic diseases and experimental models, it is possibly involved in the pathogenesis. The majority of studies on Activin A are mainly in vitro studies and for that it is interesting to validate in vivo the pathogenic potential of its deregulated expression in the lung. We overexpressed Activin A in the lungs of mice using adenoviral-mediated gene transfer. Its ectopic overexpression caused severe and sustained pulmonary pathology. We observed dynamically evolving inflammatory response degeneration of alveoli and a transient fibrotic response that followed the development of emphysema. The production of surfactant proteins was reduced dramatically and the lung function is deteriorated. Moreover, we detected high levels of Activin A in ARDS patients. Extremely important is that the therapeutic neutralization of Activin A suppressed pathology, thus proposing it as a therapeutic target for pulmonary diseases with increased levels of Activin A.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Xirakia, Charoula
- Ξηρακιά, Χαρούλα
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29963